01/08/2014 22:28:30 Free Membership Login

Cubist News (NASDAQ:CBST)

DateTimeSource
Headline
07/28/20149:00AMBWCubist to Present at August Investor Conference
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that company management will discuss Cubist’s business activities and financial outlook at investor conferences during August 2013. On Wednesday, August 6, Robert Perez, Cubist President and COO, and Michael Tomsicek, Cubist SVP and Chief Financial Officer... More...>>
07/22/20144:00PMBWCubist Reports Second Quarter 2014 Financial Results
Total Net Revenues of $294.4 Million, Up 14% Over Q2 2013 Non-GAAP Adjusted Operating Income of $41.4 Million; GAAP Operating Income of $42.2 Million Non-GAAP Diluted EPS of $0.23; GAAP Diluted EPS of $0.30 Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the second quarter ended June 30, 2014. The... More...>>
07/15/20149:00AMBWCubist to Announce Second Quarter 2014 Financial Results on Tuesday, July 22, 2014
Earnings Conference Call & Webcast at 5:00 pm ET Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its second quarter 2014 financial results at 4:00 p.m. ET on Tuesday, July 22, 2014. In connection with this announcement, Cubist will host a conference call and live audio webcast presentation at 5:00 p.m. ET that... More...>>
06/23/201410:25AMBWLe médicament SIVEXTROMC (phosphate de tedizolid), de Cubist, est approuvé aux États-Unis pour le traitement des infection...
SIVEXTRO offre aux médecins une nouvelle option : une brève série de traitements administrés par voie intraveineuse ou orale une fois par jour pendant six jours Cubist Pharmaceuticals, Inc. (NASDAQ : CBST) a annoncé aujourd'hui que la Food and Drug Administration (FDA) des États-Unis a approuvé SIVEXTROMC (phosphate... More...>>
06/22/20141:58AMBWSIVEXTRO™ (Tedizolid Phosphat) von Cubist zur Behandlung schwerer Hautinfektionen, auch durch MRSA, in den USA zugelassen
SIVEXTRO bietet Ärzten kurze, sechstätige Behandlung mit Wahlmöglichkeit zwischen einmal täglicher intravenöser oder oraler Verabreichung Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) gab heute bekannt, dass die US-Gesundheitsbehörde FDA SIVEXTRO™ (Tedizolid Phosphat) zur Behandlung erwachsener Patienten mit akuten... More...>>
06/20/20146:00PMBWCubist’s SIVEXTRO™ (tedizolid phosphate) Approved in U.S. to Treat Serious Skin Infections—Including Those Caused by MRSA
SIVEXTRO offers a short six-day course of therapy to physicians in once daily I.V. and oral treatment options Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today the U.S. Food and Drug Administration (FDA) approved SIVEXTRO™ (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure... More...>>
06/20/20149:20AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Friday's session are CarMax Inc. (KMX), Darden Restaurants Inc. (DRI) and Oracle Corp. (ORCL). AK Steel Holding Corp. (AKS) said second-quarter results will be hurt by lower production at blast furnaces, a move the company said was necessary because ice coverage... More...>>
06/19/20144:30PMBWCubist Announces Acceptance of Ceftolozane/Tazobactam New Drug Application with Priority Review
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for its investigational antibiotic ceftolozane/tazobactam with Priority Review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of... More...>>
06/06/20149:00AMBWCubist Announces Publication of Pivotal Data from SIVEXTRO™ (tedizolid phosphate) ESTABLISH-2 Clinical Trial in The Lancet ...
Results from first prospectively designed Phase 3 clinical trial consistent with final FDA guidance for acute bacterial skin and skin structure infections (ABSSSI) Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal... More...>>
06/06/20149:00AMBWCubist veröffentlicht zulassungsrelevante Daten der klinischen Studie ESTABLISH-2 zu SIVEXTRO™ (Tedizolid-Phosphat) im Jou...
Ergebnisse der ersten prospektiv konzipierten klinischen Phase-3-Studie entsprechen endgültiger FDA-Leitlinie für akute bakterielle Infektionen der Haut und Hautstrukturen Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) gab heute bekannt, dass das Journal Lancet Infectious Diseases die positiven Ergebnisse der zulassungsrelevanten... More...>>
06/06/20149:00AMBWCubist annonce la publication de résultats importants de l'essai clinique ESTABLISH-2 sur SIVEXTRO™ (phosphate de tedizoli...
Résultats du premier essai clinique prospectif de phase III conforme à la ligne directrice finale de la FDA sur les infections bactériennes aiguës de la peau et des structures cutanées (ABSSSI) Cubist Pharmaceuticals, Inc. (NASDAQ : CBST) a annoncé aujourd'hui que The Lancet Infectious Diseases a mis en ligne les... More...>>
06/02/20149:34AMBWCubist to Present at June Investor Conferences
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that company management will present at investor conferences during the month of June to discuss the company’s business activities, financial outlook, and current news. Robert Perez, President & COO, will present on Wednesday, June 11th, 2014 at 2:00 p.m... More...>>
05/09/20147:04PMBWCubist Pharmaceuticals, Inc. présente les résultats détaillés d'essais cliniques positifs de phase 3 portant sur le Cefto...
Les données provenant de ces essais cliniques montrent l'activité de l'antibiotique candidat-médicament sur les bactéries résistantes problématiques à Gram négatif chez les patients atteints d'infections compliquées Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) a annoncé aujourd'hui les premiers résultats détaillés... More...>>
05/09/20147:01PMBWCubist Presents Detailed Results from Positive Phase 3 Trials of Ceftolozane/Tazobactam at 2014 European Congress of Clinical...
Clinical trial data show antibiotic candidate’s activity against problematic resistant Gram-negative bacteria in patients with complicated infections Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the first detailed results from positive pivotal Phase 3 clinical trials of its antibiotic candidate ceftolozane/tazobactam... More...>>
05/09/20147:01PMBWCubist präsentiert detaillierte positive Ergebnisse aus der Phase-III-Studie zu Ceftolozan/Tazobactam auf dem Europäischen ...
Daten der klinischen Studie verdeutlichen die Wirkstoffe des Antibiotikums gegen problematische resistente Gram-negative Bakterien bei Patienten mit komplizierten Infektionen Cubist präsentiert detaillierte positive Ergebnisse aus der Phase-III-Studie zu Ceftolozan/Tazobactam auf dem Europäischen Kongress für klinische... More...>>
05/01/201411:46AMBWCubist présentera de nouvelles données sur les antibiotiques en développement au Congrès européen de microbiologie clini...
Premier aperçu des données détaillées des essais cliniques de phase III du ceftolozane/tazobactam pour le traitement des infections des voies urinaires compliquées et des infections intra-abdominales compliquées Cubist Pharmaceuticals, Inc. (NASDAQ : CBST) a annoncé aujourd'hui que la société présentera des données... More...>>
04/30/201411:50PMBWCubist stellt neue Ergebnisse zu seiner Antibiotika-Pipeline auf dem Europäischen Kongress für klinische Mikrobiologie und ...
Erster Blick auf ausführlichere Daten aus den klinischen Phase-3-Studien zu Ceftolozan/Tazobactam bei komplizierten Harnwegs- und intraabdominellen Infektionen Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) gab heute bekannt, dass es auf dem 24. Europäischen Kongress für klinische Mikrobiologie und Infektionskrankheiten... More...>>
04/30/201410:07AMBWCubist to Present New Antibiotics Pipeline Data at 2014 European Congress of Clinical Microbiology & Infectious Diseases (ECC...
First look at detailed data from the ceftolozane/tazobactam Phase 3 clinical trials in complicated urinary tract and intra-abdominal infections Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will present data from its late-stage antibiotics pipeline at the 24th European Congress of Clinical Microbiology... More...>>
04/23/20148:30AMBWCubist and Cambridge Science Festival Announce 2014 Germ Challenge Science Contest Winners
Teens Submit More than 20 Video Entries Describing Germs Cambridge Science Festival and Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the winners of the 2014 Germ Challenge, a contest designed to engage young people in science by inviting them to develop educational and creative videos that demonstrate their... More...>>
04/22/20144:00PMBWCubist Pharmaceuticals Reports First Quarter 2014 Financial Results
Total Net Revenues of $261.2 Million, Up 14% Over Q1 2013; U.S. CUBICIN Net Revenues of $212.2 Million, Up 5% Over Q1 2013 Non-GAAP Adjusted Operating Income of $18.8 Million; GAAP Operating Income of $28.3 Million Non-GAAP Diluted EPS of $0.10; GAAP Diluted EPS of $0.30 Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq cbst140801 22:28